BMG Pharma S.r.l

11 articles about BMG Pharma S.r.l

• Sunstar Suisse Sa Announces Its Acquisition from BMG Pharma S.p.A. of GelX® for the Treatment and Prevention of Oral Mucositis

  2/25/2019

  Through this acquisition Sunstar gains global distribution of this product line, expanding its position as a global leader in the development and commercialisation of oral healthcare products, mainly marketed under the GUM brand.

• BMG Pharma Announces the Acquisition of a Fully Patented Technology Platform and Creates New Company with Product Development Experts

  7/11/2018

  BMG Pharma S.r.l, is pleased to announce the creation of a new company (named BMG Pharma S.p.A.) with Sigea S.r.l

• BMG Pharma: GelX® Approved in Europe for Prevention of Oral Mucositis in Cancer Patients

  5/14/2018

  BMG Pharma S.r.l., an innovative specialty pharmaceutical company, is pleased to announce the European regulatory approval for its GelX product to be used for the prevention of oral mucositis.

• BMG Pharma S.r.l Announces the Launch of Its AFTACURE Gel and AFTACURE Spray under the ELGYDIUM CLINIC Brand as Cicalium Gel and Cicalium Spray by its Partner Pierre Fabre Medicament in France

  2/26/2018

  These innovative products are targeted to provide fast pain relief and promote healing for oral lesions, including aphthous ulcers.

• BMG Pharma is Pleased to Announce Positive Clinical Results on GelX the First Breakthrough Product to Achieve Prevention of Oral Mucositis in Cancer Patients

  11/15/2017

  The new clinical data, (conducted under GCP principles) from 149 adult and paediatric patients has shown unique results for the first time, with 36,2% of the patients having a complete prevention of oral mucositis during cancer therapy.

• BMG Pharma S.r.l Announces The Signature Of A Distribution Agreement For Its Cancer Supportive Care Line Including Its Iron In Liposomal Technology Based Product With Sayre Therapeutics For India And Other Asian Area Countries

  7/31/2015

• BMG Pharma S.r.l Announces The Signature Of A Distribution Agreement For Its Proprietary Product IALUXID Gel With Latam HQ Health Ltd. UK, For The Territory Of Central And South America; LatAm Hq Will Also Launch In The Same Territory Other Bmg Proprietar

  6/18/2015

• BMG Pharma S.r.l Announces The Launch Of Its Proprietary Product Ialuxid Gel Under The New Trademark HPO Skin Protect Owned By Centro Internacional De Cosmiatria, S.A.P.I. De C.V. ("FARMAPIEL") In Mexico

  5/18/2015

• Milan, Italy: BMG Pharma S.r.l Announces The Launch Of Its Proprietary Product Ialuxid Gel In The People's Republic Of China By Luqa Pharmaceuticals

  3/10/2015

• BMG Pharma S.r.l Obtained A New Indication On Molluscum Contagiosium For CE Marked Proprietary Product Ialuxid Gel

  2/9/2015

• BMG Pharma S.r.l Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To Ferrer Internacional

  1/19/2015